Latest

Related Posts

When Will Retatrutide Be Available? The Road to a 2027 FDA Filing

Not yet. Eli Lilly plans to submit retatrutide for FDA approval in the first quarter of 2027, and because a standard FDA review runs about a year from submission, the likeliest answer to when retatrutide will be available as a prescription medicine is 2028. Until then it stays investigational.

What does "investigational" mean?

An investigational drug is one still being tested in clinical trials. The FDA hasn't approved it and hasn't found it safe and effective for any use. The agency's own glossary says the same thing more plainly, calling it an experimental drug.

The label describes a stage in the approval process. It says nothing about how well the trials went. Retatrutide's have gone well.

How far along are the retatrutide trials?

Retatrutide is a single peptide chain, 39 amino acids long, that acts on three hormone receptors at once: GIP, GLP-1 and glucagon. Lilly has now run it through a phase 2 trial and a full phase 3 program called TRIUMPH, and the company says five phase 3 studies have come back positive.

Trial Reported Who took part Top-dose average weight loss
Phase 2 June 2023 Adults with obesity or overweight 24.2% at 48 weeks
TRIUMPH-4 December 2025 Adults with obesity and knee osteoarthritis 28.7% at 68 weeks
TRIUMPH-1 May 2026 2,339 adults without diabetes 28.3% at 80 weeks
TRIUMPH-2 July 2026 1,152 adults with type 2 diabetes 20.8% at 80 weeks
TRIUMPH-3 July 2026 1,949 adults with severe obesity and heart disease 22.6% at 80 weeks

Placebo groups lost far less, 2.2% in TRIUMPH-1 and 3.2% in TRIUMPH-3. Reviewers will weigh the side effects too. In TRIUMPH-1, nausea hit 42.4% of people on the highest dose against 14.8% on placebo, and 11.3% stopped treatment because of side effects, compared with 4.9%.

How long does an FDA review take?

The FDA sets a goal of acting on an application within 10 months under a standard review and within six months under a priority review. For a new molecule like retatrutide, that clock starts only after a 60-day filing period. So a submission in early 2027 points to a decision around early 2028 on the standard track, or late 2027 if the agency grants priority review, and either date can slip if reviewers ask for more data.

Approval at the end isn't automatic.

What is TRIUMPH-5?

TRIUMPH-5 is the head-to-head trial. It compares retatrutide with tirzepatide, the dual-receptor drug already on the market, in about 800 adults with obesity over 80 weeks, with change in body weight as the main measure. ClinicalTrials.gov lists data collection finishing in late 2026, so its results could arrive close to the filing date. None had been reported as of November 2026.

Why are people searching for retatrutide now?

Demand isn't waiting. The name pulls in about 271,000 US Google searches a month, according to Ahrefs, and the peptide is already sold as a freeze-dried powder by suppliers such as Astral. Readers asking about buying before approval can read a guide on whether retatrutide is legal to buy.

FAQs

Is retatrutide FDA approved?

No. As of November 2026 it is investigational, and Lilly plans to file in the first quarter of 2027.

When could retatrutide be approved?

If Lilly files on schedule and the FDA runs a standard review, a decision would come roughly a year later, in early 2028.

Has retatrutide been compared with tirzepatide?

Only across separate trials so far. TRIUMPH-5 is the direct comparison, and its results are still pending.

Sources

Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Press release, May 21, 2026.

Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. Press release, July 23, 2026.

Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 2023.

U.S. Food and Drug Administration. Priority Review. FDA patient information page.

ClinicalTrials.gov. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5). NCT06662383.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular Articles